Pills masthead

Board of Directors

Melissa V. Rewolinski, Ph.D. was appointed as a Director of the Company in July 2019.  Dr. Rewolinski has over 20 years of experience in the pharmaceutical industry. She is the founder and principal of MVR Consulting, Inc., a consulting company providing counsel to small and mid-size biotechnology and pharmaceutical companies. From 2008 through 2018, she held a number of senior executive and research and development positions at Intercept Pharmaceuticals, Inc. Previously, she held research and development positions at Amira Pharmaceuticals, Inc., Pfizer Global R&D and Pharmacia & Upjohn. Dr. Rewolinski earned a Bachelor of Science in chemistry, magna cum laude, and a Ph.D. in organic chemistry from Rice University.

John C. Chapman was appointed to the board of directors in 2018. Chapman is a retired audit partner for KPMG, having specialized in providing audit services to large complex multinational pharmaceutical and consumer market companies. During his tenure at KPMG, he served for six years as a member of the firm’s board of directors and for several years as KPMG’s global chair of pharmaceuticals and chemicals. Chapman also served as the global lead partner for some of KPMG’s largest clients, including Pfizer, Hoechst, and PepsiCo, among others. Chapman, a certified public accountant (CPA), earned a bachelor of business administration in accounting practice degree from Pace University, New York.

Paul Taveira was appointed a Director of the Company in May 2012.  Mr. Taveira has been Chief Executive Officer of the National Response Corporation, in environmental services from June 2015 through February 13, 2019.  He previously served on the Board of Directors and as the Chief Executive Officer of A&D Environmental Services Inc., an environmental and industrial services company.  From 2007 to 2009, Mr. Taveira was a Managing Partner of Precision Source LLC, a manufacturer of precision parts for various industries across the United States.  From 1997 to 2007, Mr. Taveira held several positions at PSC Inc., a national provider of environmental services, including President, Vice President and Regional General Manager.  From 1987 to 1997, Mr. Taveira held several management positions with Clean Harbors Inc., an international provider of environmental and energy services.  Mr. Taveira graduated from Worcester State University with a Bachelor of Science degree in Biology.

Patrick G. LePore was appointed as a Director of the Company in July 2017. On July 1, 2018, Mr. LePore succeeded Mr. Farber as Chairman of the Board of Directors. Mr. LePore served as Chairman, Chief Executive Officer and President of Par Pharmaceuticals, Inc., until the company’s acquisition by private equity investor TPG in 2012. He remained as chairman of the new company where he led the sale of the company to Endo Pharmaceuticals. Mr. LePore began his career with Hoffmann LaRoche. Later, he founded Boron LePore and Associates, a medical communications company, which he took public and was eventually sold to Cardinal Health. He is a member of the board of directors of PharMerica, Vice Chair of the Board of Directors of Matinas BioPharma Holdings, Inc., and is a trustee of Villanova University. Mr. LePore earned his bachelor’s degree from Villanova University and Master of Business Administration from Fairleigh Dickinson University.

David Drabik was elected to the board as an independent director by the shareholders in 2011. Since 2002, David has been president of Cranbrook & Co. LLC, an advisory firm primarily serving the private equity and venture capital community. At Cranbrook, David assists and advises clientele on originating, structuring, and executing private equity and venture capital transactions. Prior to that, he served in various roles and positions with UBS Capital Americas (and its predecessor, UBS Capital LLC), a private equity and venture capital firm that managed $1.5 billion of capital. Previously, David was a banker with Union Bank of Switzerland’s Corporate and Institutional Banking Division in New York City. David graduated from the University of Michigan with a bachelor’s degree in business administration.

Jeffrey Farber joined the Lannett Company board as secretary in 2003, was appointed director of the company in 2006, and became chairman of the board of directors in 2012. For over 13 years, Jeffrey has also been president and owner of Auburn Pharmaceutical, a national generic pharmaceutical distributor. Prior to starting Auburn, he was employed at Major Pharmaceutical for over 15 years, with roles in sales and purchasing, and eventually as president of the midwest division. Jeffrey also spent time working at Major’s manufacturing division, Vitarine Pharmaceuticals, where he served on the board of directors. Jeffrey graduated from Western Michigan University with a Bachelor of Science degree in business administration, and he participated in the Pharmacy Management Graduate Program at Long Island University.

Timothy C. Crew was appointed chief executive officer (CEO) in January 2018, having served most recently as CEO of Cipla North America, a global pharmaceutical company based in Mumbai, India, from 2013 to 2017. He was also appointed to the Lannett Company board of directors. Previously, Tim worked for eight years at Teva Pharmaceuticals, where he served as senior vice president and commercial operating officer of the North American Generics division, the world’s largest generic operation with multiple billions of dollars of annual sales. Before that, Tim was Teva’s vice president, Alliances and Business Development. From 2001 to 2004, Tim was executive vice president, North America, for Dr. Reddy’s Laboratories.

Tim began his pharmaceutical career at Bristol-Myers Squibb, where he held a number of senior management positions in global marketing, managed healthcare, marketing, business development, and strategic planning. Prior to his pharmaceutical roles, Tim served in the United States Army, where he rose to the rank of captain.